The side effects were described by the MHRA as being the same as for the original Moderna booster dose and found to be “typically mild and self-resolving.”
“No serious safety concerns were identified,” the UK government release said.
As Covid-19 continues to mutate
, MHRA Chief Executive Dr. June Raine said that the new Moderna booster will help keep communities protected.
“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives. What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”
It is not yet clear who will be offered the booster or when. The UK’s Joint Committee on Vaccination and Immunisation (JCVI) will advise on the vaccine’s rollout.
Stéphane Bancel, Chief Executive Officer of Moderna, said
on Twitter he was “delighted” the vaccine had been approved.
“This represents the first authorization of an Omicron-containing bivalent vaccine, this bivalent vaccine has an important role to play in protecting people in the UK from Covid-19 as we enter the winter months,” he said.
Moderna is not the only vaccine maker updating its Covid-19 vaccines.
In June, Pfizer and BioNTech tested two Covid-19 vaccine boosters to target the Omicron variant. The companies said that preliminary results show a substantially higher immune response than the current Covid-19 shots.